Life Science REIT plc (LON:LABS - Get Free Report) shares traded down 4.9% on Monday . The company traded as low as GBX 39 ($0.49) and last traded at GBX 39 ($0.49). 583,238 shares were traded during mid-day trading, a decline of 43% from the average session volume of 1,031,143 shares. The stock had previously closed at GBX 41 ($0.52).
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on LABS shares. Shore Capital restated a "buy" rating on shares of Life Science REIT in a report on Thursday, September 26th. Berenberg Bank reissued a "buy" rating and set a GBX 57 ($0.72) price objective on shares of Life Science REIT in a research report on Thursday, October 3rd. Finally, Jefferies Financial Group lowered their price objective on Life Science REIT from GBX 45 ($0.57) to GBX 36 ($0.46) and set a "hold" rating for the company in a research report on Friday, August 30th.
Check Out Our Latest Analysis on LABS
Life Science REIT Stock Performance
The firm has a 50-day moving average price of GBX 38.49 and a 200-day moving average price of GBX 36.13. The stock has a market cap of £138.95 million, a PE ratio of -659.25 and a beta of 0.08.
Life Science REIT Dividend Announcement
The firm also recently announced a dividend, which was paid on Thursday, October 31st. Shareholders of record on Thursday, October 3rd were given a GBX 1 ($0.01) dividend. This represents a yield of 3.11%. The ex-dividend date was Thursday, October 3rd. Life Science REIT's dividend payout ratio (DPR) is -3,333.33%.
About Life Science REIT
(
Get Free Report)
Life Science REIT plc (the Company) is a closed-ended Real Estate Investment Trust (REIT) incorporated in England and Wales on 27 July 2021. The Company began trading on 19 November 2021 and its shares are admitted to trading on the Premium Listing Segment of the Main Market of the London Stock Exchange.
Further Reading
Before you consider Life Science REIT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Life Science REIT wasn't on the list.
While Life Science REIT currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
